| Aaron P Kurjan, DO | |
|
4100 Park Forest Dr, Suite 210, Traverse City, MI 49684-7331 | |
| (231) 935-5770 | |
| (231) 935-0747 |
| Full Name | Aaron P Kurjan |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 19 Years |
| Location | 4100 Park Forest Dr, Traverse City, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1366600066 | NPI | - | NPPES |
| 1366600066 | Medicaid | MI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 5101018085 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Munson Medical Center | Traverse city, MI | Hospital |
| Munson Healthcare Manistee Hospital | Manistee, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Munson Medical Group | 8820277015 | 135 |
News Archive
Vertex Pharmaceuticals Incorporated today announced the initiation of a Phase 2a clinical trial that will evaluate multiple combinations of VX-770 and VX-809, investigational oral cystic fibrosis transmembrane conductance regulator (CFTR) modulators for the treatment of cystic fibrosis (CF). The trial is designed to evaluate the safety and tolerability of VX-809 dosed alone for 14 days followed by dosing of VX-809 in combination with VX-770 for 7 days.
In what the department described as its "first guidance" in the wake of the Supreme Court striking down the Defense of Marriage Act, HHS said that all Medicare Advantage enrollees, including same-sex couples, will have equal access to coverage in a nursing home.
Raptor Pharmaceutical Corp., announced that the Company has acquired an exclusive worldwide license to intellectual property related to the potential treatment of Huntington's Disease from the Weizmann Institute of Science in Israel and Niigata University in Japan. In addition, Raptor has added Professor Lawrence Steinman, M.D., an inventor on the Weizmann patent, to its Advisory Board.
Bruker today announced that it has signed an agreement to acquire Michrom Bioresources, Inc., a 20 year old, privately owned company based in Auburn, California. Michrom provides liquid chromatography instrumentation, accessories, and consumables for applications in the life science, chemical and applied markets.
› Verified 8 days ago
| Entity Name | Traverse Anesthesia Associates, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013966506 PECOS PAC ID: 5597750091 Enrollment ID: O20040415000437 |
News Archive
Vertex Pharmaceuticals Incorporated today announced the initiation of a Phase 2a clinical trial that will evaluate multiple combinations of VX-770 and VX-809, investigational oral cystic fibrosis transmembrane conductance regulator (CFTR) modulators for the treatment of cystic fibrosis (CF). The trial is designed to evaluate the safety and tolerability of VX-809 dosed alone for 14 days followed by dosing of VX-809 in combination with VX-770 for 7 days.
In what the department described as its "first guidance" in the wake of the Supreme Court striking down the Defense of Marriage Act, HHS said that all Medicare Advantage enrollees, including same-sex couples, will have equal access to coverage in a nursing home.
Raptor Pharmaceutical Corp., announced that the Company has acquired an exclusive worldwide license to intellectual property related to the potential treatment of Huntington's Disease from the Weizmann Institute of Science in Israel and Niigata University in Japan. In addition, Raptor has added Professor Lawrence Steinman, M.D., an inventor on the Weizmann patent, to its Advisory Board.
Bruker today announced that it has signed an agreement to acquire Michrom Bioresources, Inc., a 20 year old, privately owned company based in Auburn, California. Michrom provides liquid chromatography instrumentation, accessories, and consumables for applications in the life science, chemical and applied markets.
› Verified 8 days ago
| Entity Name | Kalkaska Memorial Health Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013183060 PECOS PAC ID: 3577536002 Enrollment ID: O20040813000668 |
News Archive
Vertex Pharmaceuticals Incorporated today announced the initiation of a Phase 2a clinical trial that will evaluate multiple combinations of VX-770 and VX-809, investigational oral cystic fibrosis transmembrane conductance regulator (CFTR) modulators for the treatment of cystic fibrosis (CF). The trial is designed to evaluate the safety and tolerability of VX-809 dosed alone for 14 days followed by dosing of VX-809 in combination with VX-770 for 7 days.
In what the department described as its "first guidance" in the wake of the Supreme Court striking down the Defense of Marriage Act, HHS said that all Medicare Advantage enrollees, including same-sex couples, will have equal access to coverage in a nursing home.
Raptor Pharmaceutical Corp., announced that the Company has acquired an exclusive worldwide license to intellectual property related to the potential treatment of Huntington's Disease from the Weizmann Institute of Science in Israel and Niigata University in Japan. In addition, Raptor has added Professor Lawrence Steinman, M.D., an inventor on the Weizmann patent, to its Advisory Board.
Bruker today announced that it has signed an agreement to acquire Michrom Bioresources, Inc., a 20 year old, privately owned company based in Auburn, California. Michrom provides liquid chromatography instrumentation, accessories, and consumables for applications in the life science, chemical and applied markets.
› Verified 8 days ago
| Entity Name | Kalkaska Memorial Health Center |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1497751309 PECOS PAC ID: 3577536002 Enrollment ID: O20080219000532 |
News Archive
Vertex Pharmaceuticals Incorporated today announced the initiation of a Phase 2a clinical trial that will evaluate multiple combinations of VX-770 and VX-809, investigational oral cystic fibrosis transmembrane conductance regulator (CFTR) modulators for the treatment of cystic fibrosis (CF). The trial is designed to evaluate the safety and tolerability of VX-809 dosed alone for 14 days followed by dosing of VX-809 in combination with VX-770 for 7 days.
In what the department described as its "first guidance" in the wake of the Supreme Court striking down the Defense of Marriage Act, HHS said that all Medicare Advantage enrollees, including same-sex couples, will have equal access to coverage in a nursing home.
Raptor Pharmaceutical Corp., announced that the Company has acquired an exclusive worldwide license to intellectual property related to the potential treatment of Huntington's Disease from the Weizmann Institute of Science in Israel and Niigata University in Japan. In addition, Raptor has added Professor Lawrence Steinman, M.D., an inventor on the Weizmann patent, to its Advisory Board.
Bruker today announced that it has signed an agreement to acquire Michrom Bioresources, Inc., a 20 year old, privately owned company based in Auburn, California. Michrom provides liquid chromatography instrumentation, accessories, and consumables for applications in the life science, chemical and applied markets.
› Verified 8 days ago
| Entity Name | Munson Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821398322 PECOS PAC ID: 8820277015 Enrollment ID: O20110120000061 |
News Archive
Vertex Pharmaceuticals Incorporated today announced the initiation of a Phase 2a clinical trial that will evaluate multiple combinations of VX-770 and VX-809, investigational oral cystic fibrosis transmembrane conductance regulator (CFTR) modulators for the treatment of cystic fibrosis (CF). The trial is designed to evaluate the safety and tolerability of VX-809 dosed alone for 14 days followed by dosing of VX-809 in combination with VX-770 for 7 days.
In what the department described as its "first guidance" in the wake of the Supreme Court striking down the Defense of Marriage Act, HHS said that all Medicare Advantage enrollees, including same-sex couples, will have equal access to coverage in a nursing home.
Raptor Pharmaceutical Corp., announced that the Company has acquired an exclusive worldwide license to intellectual property related to the potential treatment of Huntington's Disease from the Weizmann Institute of Science in Israel and Niigata University in Japan. In addition, Raptor has added Professor Lawrence Steinman, M.D., an inventor on the Weizmann patent, to its Advisory Board.
Bruker today announced that it has signed an agreement to acquire Michrom Bioresources, Inc., a 20 year old, privately owned company based in Auburn, California. Michrom provides liquid chromatography instrumentation, accessories, and consumables for applications in the life science, chemical and applied markets.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Aaron P Kurjan, DO 4100 Park Forest Dr, Suite 210, Traverse City, MI 49684-7331 Ph: (231) 935-5770 | Aaron P Kurjan, DO 4100 Park Forest Dr, Suite 210, Traverse City, MI 49684-7331 Ph: (231) 935-5770 |
News Archive
Vertex Pharmaceuticals Incorporated today announced the initiation of a Phase 2a clinical trial that will evaluate multiple combinations of VX-770 and VX-809, investigational oral cystic fibrosis transmembrane conductance regulator (CFTR) modulators for the treatment of cystic fibrosis (CF). The trial is designed to evaluate the safety and tolerability of VX-809 dosed alone for 14 days followed by dosing of VX-809 in combination with VX-770 for 7 days.
In what the department described as its "first guidance" in the wake of the Supreme Court striking down the Defense of Marriage Act, HHS said that all Medicare Advantage enrollees, including same-sex couples, will have equal access to coverage in a nursing home.
Raptor Pharmaceutical Corp., announced that the Company has acquired an exclusive worldwide license to intellectual property related to the potential treatment of Huntington's Disease from the Weizmann Institute of Science in Israel and Niigata University in Japan. In addition, Raptor has added Professor Lawrence Steinman, M.D., an inventor on the Weizmann patent, to its Advisory Board.
Bruker today announced that it has signed an agreement to acquire Michrom Bioresources, Inc., a 20 year old, privately owned company based in Auburn, California. Michrom provides liquid chromatography instrumentation, accessories, and consumables for applications in the life science, chemical and applied markets.
› Verified 8 days ago
Brian M Kiessling, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 4100 Park Forest Dr, Suite 210, Traverse City, MI 49684 Phone: 231-935-5770 Fax: 231-935-0747 | |
Kamala Wright, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 4100 Park Forest Dr, Suite 210, Traverse City, MI 49684 Phone: 231-935-5770 Fax: 231-935-0747 | |
Raymond J Omerza, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 4100 Park Forest Dr, Suite 210, Traverse City, MI 49684 Phone: 231-935-5770 Fax: 231-935-0747 | |
Charles Kerndt, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 4100 Park Forest Dr, Suite 210, Traverse City, MI 49684 Phone: 231-935-5770 Fax: 231-935-0747 | |
David S Feenstra, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 4100 Park Forest Dr, Suite 210, Traverse City, MI 49684 Phone: 231-935-5770 Fax: 231-935-0747 | |
Dr. Donald E. Kring Jr., D.O. Anesthesiology Medicare: Medicare Enrolled Practice Location: 4100 Park Forest Dr, Suite 210, Traverse City, MI 49684 Phone: 231-935-5770 Fax: 231-935-5878 | |
Edward C Vomastek, DO Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 4100 Park Forest Dr, Suite 210, Traverse City, MI 49684 Phone: 231-935-5770 Fax: 231-935-0747 |